Showing 4571-4580 of 6036 results for "".
- MYZE Eye Health Focused Digital Platform Launchedhttps://modernod.com/news/myze-eye-health-focused-digital-platform-launched/2481138/MYZE is a eye care engagement platform designed to help identify, treat, and manage dry eyes. It is designed to simplify the burden of dry eye identification and management by enabling “always available” screenings followed by frictionless access to products, servi
- EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathyhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-pavia-trial-of-eyp-1901-for-the-treatment-of-non-proliferative-diabetic-retinopathy/2481131/EyePoint Pharmaceuticals announced that the first patient has been dosed in the phase 2 PAVIA clinical trial of EYP-1901, a potential sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting non-proliferative diabetic retinopathy (NPDR).
- Neurophth Announces First Patient Dosed in Phase 3 Clinical Trial for the Gene Therapy Treatment of LHONhttps://modernod.com/news/neurophth-announces-first-patient-dosed-in-phase-3-clinical-trial-for-the-gene-therapy-treatment-of-lhon/2481126/Neurophth Therapeutics announced that the first patient has been dosed in phase 3 clinical trial for the treatment of Leber hereditary optic neuropathy (LHON). Neurophth is conducting a phase 1/2/3, multicenter, two-part study aimed at evaluating the safety, tolerability, and effic
- Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the Omni Surgical System as a Standalone Glaucoma Treatment at AAOhttps://modernod.com/news/sight-sciences-to-feature-interactive-panel-discussions-of-real-world-use-of-the-omni-surgical-system-as-a-standalone-glaucoma-treatment-at-aao/2481125/Sight Sciences announced that 12 ophthalmic physicians will present their first-hand experience using the Omni Surgical System as a standalone minimally invasive glaucoma surgery (MIGS) during this year’s annual AAO convention at McCormick Place in Chicago. Meeting delegates are invite
- Visus Therapeutics Acquires Assets of ViewPoint Therapeuticshttps://modernod.com/news/visus-therapeutics-acquires-assets-of-viewpoint-therapeutics/2481124/Visus Therapeutics announced it has expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics. Financial terms of the deal were not disclosed. Founded in 2014, ViewPoint discovered and developed alpha-crystallin aggregation
- Tarsus Presents Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Datahttps://modernod.com/news/tarsus-to-present-saturn-2-pivotal-phase-3-trial-data-and-saturn-1-extension-study-long-term-safety-data-at-upcoming-eye-care-meetings/2481123/Tarsus Pharmaceuticals announced that the results from the Saturn-2 pivotal phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) in Demodex blepharitis patients will be presented at the upcoming World Cornea Congress (WCC) VIII and the American Academy of Ophthalmology
- Ocular Therapeutix Announces Interim 7-month Data from US Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-interim-7-month-data-from-us-phase-1-clinical-trial-of-otx-tki-for-the-treatment-of-wet-amd/2481120/Ocular Therapeutix announced interim 7-month data from its US phase 1 clinical trial evaluating OTX-TKI, the company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases. The data will b
- Amydis Enrolls First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Diseasehttps://modernod.com/news/amydis-announces-enrollment-of-first-participants-in-probe-a-phase-12a-trial-evaluating-a-novel-retinal-tracer-in-people-with-amyotrophic-lateral-sclerosis-or-parkinsons-disease/2481109/Amydis announced dosing of the first patients in the company’s phase 1/2a trial evaluating AMDXP-2011P, a proprietary small molecule retinal imaging agent “retinal tracer” targeting deposits of alpha synuclein (ASYN) and the TAR DNA-binding protein 43 (TDP-43) in patients w
- Atsena Therapeutics Announces Late-Breaker Presentation at the AAO Annual Meetinghttps://modernod.com/news/atsena-therapeutics-announces-late-breaker-presentation-at-the-aao-annual-meeting/2481107/Atsena Therapeutics announced that data from the phase 1/2 clinical trial of ATSN-101 will be presented in a late breaking developments session during the Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO 2022), which is being held Sept
- European Commission Approves Roche’s Vabysmo for Wet AMD and DMEhttps://modernod.com/news/european-commission-approves-roches-vabysmo-for-wet-amd-and-dme/2481102/Roche announced that the European Commission (EC) approved Vabysmo (faricimab) for the treatment of wet age-related macular degeneration (AMD) and visual impairment due to diabetic macular edema (DME). “Many people with nAMD and DME struggle to keep up with the mont